Companies in #Antibodies

Preclinical-stage oncology biotechnology company developing antibody therapeutics and diagnostics targeting the ADAM8 cell-surface protein, a driver of multiple aggressive cancers.

Secondary Research Antibodies

Clinical-stage biotechnology company in Redmond, Washington, developing bispecific and multi-specific antibodies and antibody-drug conjugates for solid tumor and hematologic cancers; its September 2026 FDA IND clearance for SI-B037 was the company's first IND built on New Approach Methodologies.